← Latest papers
📄 cell biology

Conformation governs cellular behaviors of LRRK2 Parkinson's disease variants

This study establishes that "unlatching" mutations in LRRK2, which disrupt its autoinhibited conformation to increase membrane localization and substrate phosphorylation, serve as a unifying mechanism for most Parkinson's disease-linked variants and provide measurable conformational biomarkers for disease identification.

Original authors: Hatch, K. S., Surridge, K. J., Gai, W., Quan, B., Kumar, G., Lattal, N., Abrisch, R., Pagani, N., Leschziner, A. E., Reck-Peterson, S. L.

Published 2026-11-02
📖 5 min read🧠 Deep dive

Original authors: Hatch, K. S., Surridge, K. J., Gai, W., Quan, B., Kumar, G., Lattal, N., Abrisch, R., Pagani, N., Leschziner, A. E., Reck-Peterson, S. L.

Original paper licensed under CC BY 4.0 (https://creativecommons.org/licenses/by/4.0/). ⚕️ This is an AI-generated explanation of a preprint that has not been peer-reviewed. It is not medical advice. Do not make health decisions based on this content. Read full disclaimer

Parkinson's disease is a condition that slowly disrupts the brain's ability to control movement, affecting millions of people worldwide. While many cases appear without a clear genetic cause, a significant number of families carry a specific error in a gene called LRRK2. This gene provides instructions for building a large protein that acts as a molecular switch, turning on and off to help cells manage their internal transport systems. In healthy individuals, this protein is kept in a safe, inactive state until it is needed. However, in people with certain genetic variants, this switch gets stuck in the "on" position, leading to a toxic buildup of activity that damages nerve cells. Understanding exactly how these genetic errors jam the switch is crucial, because it could reveal new ways to treat the disease, not just for those with the mutation but potentially for others as well.

For years, scientists have known that different mutations in the LRRK2 gene cause the protein to misbehave, but they did not fully understand the mechanical steps involved. Some mutations were thought to work by directly speeding up the protein's chemical reactions, while others seemed to act differently, perhaps by changing the protein's shape. A team of researchers at Weill Cornell Medicine and the University of California, San Diego, set out to solve this puzzle by watching how these mutated proteins behave inside living cells. They focused on a specific part of the protein's structure: a long, flexible tail made of repeating segments that usually folds over the protein's active center to block it, like a safety cover. The researchers proposed that for the protein to work, this cover must be lifted off, a process they call "unlatching."

The team discovered that a large group of Parkinson's-linked mutations works by making it much easier for this safety cover to unlatch. They tested several common mutations, including those found in the R1441 and Y1699 regions, and found that these changes destabilize the protein's locked state. When the cover lifts, the protein becomes primed for action and moves more readily to the cell's membranes, where its targets are located. This movement is critical because the protein only harms the cell when it is active on these membranes. The researchers also found a reliable way to see this unlatching happening. They observed that when the safety cover is lifted, a specific chemical tag on the protein, known as S935, disappears. This tag acts like a molecular fingerprint: its presence means the protein is locked and safe, while its absence signals that the protein is unlocked and potentially dangerous.

Not all mutations follow this same path. The researchers confirmed that the most common mutation, known as G2019S, does not work by unlatching the safety cover. Instead, this mutation appears to act directly on the engine of the protein, making it run faster even when the cover is still in place. This distinction is vital because it means that different patients with Parkinson's disease may have the same disease outcome caused by two completely different mechanical failures. One group has a broken lock, while the other has a revved-up engine. This finding helps explain why some mutations cause the protein to gather on cell membranes more aggressively than others, a behavior that was previously difficult to predict.

The study also shed light on a mutation called I2020T, which sits right next to the G2019S mutation in the protein's structure. Because they are so close, scientists had assumed they worked the same way. However, the researchers found that I2020T behaves like the "unlatching" group, not the "engine" group. Despite its location, this mutation encourages the safety cover to lift, leading to increased membrane association and a loss of the protective S935 tag. Yet, I2020T is unique because it also seems to weaken the protein's own power, creating a complex mix of effects where it unlocks the safety cover but struggles to run the engine efficiently. This dual nature explains why previous studies on this mutation have produced conflicting results, depending on how the experiments were set up.

By mapping out these different behaviors, the researchers have created a new framework for understanding Parkinson's disease. They showed that the key to many of these genetic errors is not just how fast the protein works, but how its shape changes to allow it to work in the first place. The loss of the S935 tag serves as a clear, measurable sign that the protein has shifted into this dangerous, unlocked state. This insight suggests that doctors and scientists could potentially use this tag to sort patients into different groups based on the specific mechanical failure driving their disease. Such a classification could lead to more precise treatments, targeting the specific way a patient's protein is broken rather than applying a one-size-fits-all approach. The work confirms that the shape of a protein is just as important as its speed in determining whether it will cause disease, offering a clearer path forward for developing therapies that can restore the natural balance within the cell.

Drowning in papers in your field?

Get daily digests of the most novel papers matching your research keywords — with technical summaries, in your language.

Try Digest →